Although the break-up of the deal with Shire cost investors $2.23 billion in related expenses and significantly muddied AbbVie's profitability last quarter, the company's cost-cutting moves were evident in its cost of goods sold, which fell from 25.08% a year ago to 20.52% in the fourth quarter. Source: AbbVie & author's calculations. Looking ahead All eyes are looking toward first-quarter 2015 earnings results to see how much market share Viekira Pak can wrestle away from hepatitis C treatment leader Gilead Sciences.